FOxTROT trial: Neoadjuvant Therapy for Colon Cancer
Posted in Lectures on 22 September 2014
Dion Morton (Professor of Surgery – School of Cancer)
Queen Elizabeth Hospital Birmingham (Old), Birmingham, United Kingdom
A percentage of patients with colon cancer treated with curative intention died despite of receiving a correct surgery and complementary adjuvant therapy. This fact awakes the necessity of remodeling the approach.
Recently a well designed multicenter trial comes from the collaboration between the University of Birmingham and the Cancer Research UK Organization. The proposal is to give neoadjuvant treatment for patients with high risk of colon cancer with the intention to reduce the recurrence after surgery among other objectives.
Dion Morton justifies the trial and explain its design, he said “I think it is not the trial, it is the first trial” to explain the impact of this investigation.
One of the potentials benefits is the downsizing and downstaging of the tumor, increasing the number of cases with a proper surgical treatment improving the oncological outcomes.
In summary, this study represents a mind changing trial delivered safely to carefully selected patients.